Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2013 Dec 31;8(12):e84091. doi: 10.1371/journal.pone.0084091. eCollection 2013.

Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection.

Author information

1
Department of Bioengineering and Therapeutic Sciences, Department of Pharmacy, University of California San Francisco, San Francisco, California, United States of America ; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
2
Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America ; Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America.
3
Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America ; Core Immunology Laboratory, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
4
Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
5
Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America ; Division of Rheumatology, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
6
Department of Bioengineering and Therapeutic Sciences, Department of Pharmacy, University of California San Francisco, San Francisco, California, United States of America.
7
Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
8
Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America ; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.

Abstract

HIV-mediated immune dysfunction may influence CD4(+) T cell recovery during suppressive antiretroviral therapy (ART). We analyzed cellular biomarkers of immunological inflammation, maturation, and senescence in HIV-infected subjects on early suppressive ART. We performed longitudinal analyses of peripheral immunological biomarkers of subjects on suppressive ART (n = 24) from early treatment (median 6.4 months, interquartile range [IQR] 4.8-13.9 months) to 1-2 years of follow-up (median 19.8 months, IQR 18.3-24.6 months). We performed multivariate regression to determine which biomarkers were associated with and/or predictive of CD4(+) T cell recovery. After adjusting for the pre-ART CD4(+) T cell count, age, proximal CD4(+) T cell count, and length of ART medication, the percentage of CD27(+)CD8(+) T cells remained significantly associated with the CD4(+) T cell recovery rate (β = 0.092 cells/ul/month, P = 0.028). In HIV-infected subjects starting suppressive ART, patients with the highest percentage of CD8(+) T cells expressing CD27 had the greatest rate of CD4(+) T cell recovery.

PMID:
24391889
PMCID:
PMC3877182
DOI:
10.1371/journal.pone.0084091
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center